WNTinib Is a Multi-Kinase Inhibitor with Specificity against β-Catenin Mutant Hepatocellular Carcinoma

Using chemical libraries derived from clinical multi-kinase inhibitor (KI) scaffolds, investigators screened HCC organoids to identify WNTinib, a KI with exquisite selectivity in CTNNB1-mutated human and murine models, including patient samples.